10 - Role of Immunohistochemical Expression of Cyclooxygenase and Peroxisome Proliferator–Activated Receptor γ in Epithelial Ovarian Tumors

[1]  B. Davis,et al.  Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. , 2004, Gynecologic oncology.

[2]  M. Santoro,et al.  Inhibitory Effects of Peroxisome Proliferator-Activated Receptor γ on Thyroid Carcinoma Cell Growth , 2002 .

[3]  N. Maggiano,et al.  Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  T. Zander,et al.  Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ , 2002 .

[5]  C. Denkert,et al.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. , 2002, The American journal of pathology.

[6]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[7]  A. Ristimäki,et al.  Cyclooxygenase‐2 expression during carcinogenesis in the human stomach , 2002, The Journal of pathology.

[8]  W. Wahli,et al.  Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. , 2001, Endocrinology.

[9]  O. Ishiko,et al.  Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. , 2001, International journal of molecular medicine.

[10]  K. Subbaramaiah,et al.  Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. , 2001, Endocrine-related cancer.

[11]  M. Dietel,et al.  Serous tumors of low malignant potential of the ovary-molecular pathology: part 2 , 2001, Virchows Archiv.

[12]  K. Subbaramaiah,et al.  Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. , 2001, The Journal of biological chemistry.

[13]  J. Holden,et al.  Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[14]  S. Ishihara,et al.  Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists , 2000, British Journal of Cancer.

[15]  K. Umesono,et al.  Feedback control of cyclooxygenase-2 expression through PPARgamma. , 2000, The Journal of biological chemistry.

[16]  K. Seibert,et al.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. , 2000, Cancer research.

[17]  R. Mansel,et al.  Peroxisome proliferator activated receptor-γ (PPAR-γ) mediates the action of gamma linolenic acid in breast cancer cells , 2000 .

[18]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[19]  N. Kamada,et al.  Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids. , 1999, International journal of oncology.

[20]  M. Willingham,et al.  Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. , 1999, Carcinogenesis.

[21]  M. Mitchell,et al.  15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. , 1999, Biochemical and biophysical research communications.

[22]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[23]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[24]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Spiegelman,et al.  Terminal differentiation of human breast cancer through PPAR gamma. , 1998, Molecular cell.

[26]  William L. Smith,et al.  Prostaglandin Endoperoxide H Synthases (Cyclooxygenases)-1 and −2* , 1996, The Journal of Biological Chemistry.

[27]  Raymond L. White,et al.  Self-Promotion? Intimate Connections Between APC and Prostaglandin H Synthase-2 , 1996, Cell.

[28]  J. Otto,et al.  Photolabeling of Prostaglandin Endoperoxide H Synthase-1 with 3-Trifluoro-3-(m-Iiodophenyl)diazirine as a Probe of Membrane Association and the Cyclooxygenase Active Site (*) , 1996, The Journal of Biological Chemistry.

[29]  K. Shigemasa,et al.  Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. , 2003, International journal of oncology.

[30]  A. Badawi,et al.  Expression of cyclooxygenase‐2 and peroxisome proliferator‐activated receptor‐γ and levels of prostaglandin E2 and 15‐deoxy‐Δ12,14‐prostaglandin J2 in human breast cancer and metastasis , 2003 .